GRI Bio, Inc. Reports Second Quarter Net Loss of $6.7 Million

GRI Bio, Inc.(GRI), a leading player i n the biotechnology sector, recently released its unaudited interim consolidated financial statements for the second quarter of 2023. The report showcases a net loss of $6.7 million, alongside significant changes in its financial landscape. The company's revenue and net income/loss have been closely examined to provide insights into its performance over the last quarter.

Net Income/Loss Highlights

The financial report reveals that GRI Bio, Inc. recorded a net loss of $6.7 million for the second quarter of 2023. This figure reflects a stark contrast compared to the same period last year when the company reported a net loss of $295,000. The substantial change in net loss highlights the company's ongoing efforts to navigate challenges and opportunities within the industry.

Revenue Highlights